Mårten Winge new CEO

Strike Pharma, (“STRIKE”) a Swedish start-up company focused on personalized immunotherapy, today announced the appointment of Pyrosequencing and Olink veteran Mårten Winge as Chief Executive Officer. Founded in 2020 out of Uppsala University, Strike Pharma’s vision is to provide affordable and scalable personalized immunotherapy solutions for the treatment of solid tumors by commercializing the company’s proprietary ADAC technology (formerly referred to as Immune Gas Pedal – IMMGAP technology).

ADAC technology is based on research by Associate Professor Sara Mangsbo at Uppsala University and has been co-developed with the Drug Discovery and Development Platform of SciLifeLab – an institution for the advancement of molecular biosciences in Sweden. While the primary focus is cancer, Strike Pharma believe that this technology has the potential to become a generic delivery method for any type of disease.

Over the past twenty years, Mårten Winge has held executive management and board positions at Pyrosequencing, Olink, Halo Genomics and Proxeon. Most recently he was CEO of Cartana AB which was acquired by 10x Genomics. He is currently on the board of Countagen and Inhalation Sciences, acts as an advisor to Inossia, and is a business coach for Uppsala Innovation Center. He has a Master of Science degree in Molecular Biology from Karolinska Institute, Stockholm.

“This technology effectively utilizes our own bodies as factories to produce immune cells that can later be used to eliminate tumors. Our ambition is to transform the development of individualized cancer therapies,” says Mangsbo. “Mårten has extensive experience of international marketing and business development when commercializing new technology in the life science market, primarily in start-up and early growth companies. His business skills and experience will enable Strike Pharma to move into the next phase of business and corporate development. I am pleased to welcome him onboard.”

“I am delighted to have the opportunity to work with this extraordinarily talented and knowledgeable team of individuals. I believe that Strike Pharma is remarkably well positioned to have a major impact on the rapidly developing field of precision medicine and future individualized treatments,” commented Winge. With Mårten as CEO, Wing Cheng, the former CEO, will focus on quality assurance, regulatory compliance and market access to enable a successful transition into clinical use. The team has also been strengthened by a scientific advisor, Associate Professor Johan Botling, who will provide expert advice on the road to clinical entry based on his experience implementing molecular diagnostics for tailored cancer therapies and immune-oncology over the past 15 years.